Alterations in liver, muscle, and adipose tissue insulin sensitivity in men with HIV infection and dyslipidemia

American Journal of Physiology - Endocrinology and Metabolism

Volumn 290, Issue 1, 2006, Pages

  Reeds, D N ^a   Yarasheski, K E ^a   Fontana, L ^a,b   Cade, W T ^a   Laciny, E ^a   DeMoss, A ^a   Patterson, B W ^a   Powderly, W G ^c   Klein, S ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^c UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

Adipokine; Hepatic steatosis; Insulin resistance

Indexed keywords

ADIPONECTIN; ANTIRETROVIRUS AGENT; ATAZANAVIR; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INDINAVIR; INSULIN; INTERLEUKIN 6; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; PALMITIC ACID; PROTEINASE INHIBITOR; STAVUDINE; TRIACYLGLYCEROL; FATTY ACID;

ADIPOSE TISSUE; ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DYSLIPIDEMIA; ENERGY EXPENDITURE; GLUCONEOGENESIS; GLUCOSE METABOLISM; GLUCOSE OXIDATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPOLYSIS; LIVER LEVEL; MALE; MUSCLE LEVEL; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; BODY COMPOSITION; COMPARATIVE STUDY; DRUG EFFECT; ENERGY METABOLISM; GLUCOSE BLOOD LEVEL; GLUCOSE CLAMP TECHNIQUE; LIVER; METABOLISM; MIDDLE AGED; OXIDATION REDUCTION REACTION; PHYSIOLOGY; SKELETAL MUSCLE;

ADIPONECTIN; ADIPOSE TISSUE; ADULT; BLOOD GLUCOSE; BODY COMPOSITION; CHOLESTEROL, HDL; DYSLIPIDEMIAS; ENERGY METABOLISM; FATTY ACIDS, NONESTERIFIED; GLUCOSE; GLUCOSE CLAMP TECHNIQUE; HIV INFECTIONS; HUMANS; INSULIN; INSULIN RESISTANCE; LIVER; MALE; MIDDLE AGED; MUSCLE, SKELETAL; OXIDATION-REDUCTION; PALMITIC ACID; TRIGLYCERIDES;

EID: 33644878714     PISSN: 01931849     EISSN: 15221555     Source Type: Journal    
DOI: 10.1152/ajpendo.00236.2005     Document Type: Article

References (49)

1. Barbaro G, Lorenzo GD, Cirelli A, Grisorio B, Lucchini A, Hazra C, and Barbarini G. An open-label, prospective, observational study of the incidence of coronary artery disease in patients with hiv infection receiving highly active antiretroviral therapy. Clin Therapeut 25: 2405-2418, 2003.
2. Behrens G, Dejam A, Schmidt H, Balks HJ, Brabant G, Korner T, Stoll M, and Schmidt RE. Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors. AIDS 13: F63-F70, 1999.
3. Behrens GM, Stoll M, and Schmidt RE. Lipodystrophy syndrome in HIV infection: what is it, what causes it and how can it be managed? Drug Saf 23: 57-76, 2000.
4. Berg AH, Combs TP, Du X, Brownlee M, and Scherer PE. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med 7: 947-953, 2001.
5. Carpentier A, Patterson BW, Uffelman KD, Salit I, and Lewis GF. Mechanism of highly active anti-retroviral therapy-induced hyperlipidemia in HIV-infected individuals. Atherosclerosis 178: 165-172, 2005.
6. Carr A, Emery S, Law M, Puls R, Lundgren JD, and Powderly WG. An objective case definition of lipodystrophy in HIV-infected adults: a case-control study. Lancet 361: 726-735, 2003.
7. Carr A and Law M. An objective lipodystrophy severity grading scale derived from the lipodystrophy case definition score. J Acquir Immune Defic Syndr 33: 571-576, 2003.
8. Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm DJ, and Cooper DA. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 12: F51-F58, 1998.
9. Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, and Cooper DA. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 353: 2093-2099, 1999.
10. Castelli WP. The triglyceride issue: a view from Framingham. Am Heart J 112: 432-437, 1986.
11. Criqui MH, Heiss G, Cohn R, Cowan LD, Suchindran CM, Bangdiwala S, Kritchevsky S, Jacobs DR Jr, O'Grady HK, and Davis CE. Plasma triglyceride level and mortality from coronary heart disease. N Engl J Med 328: 1220-1225, 1993.
12. DeFronzo RA and Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 14: 173-194, 1991.
13. Ferrannini E. The theoretical bases of indirect calorimetry: a review. Metabolism 37: 287-301, 1988.
14. Friedewald WT, Levy RI, and Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18: 499-502, 1972.
15. Friis-Moller N, Sabin CA, Weber R, d'Arminio MA, El Sadr WM, Reiss P, Thiebaut R, Morfeldt L, De Wit S, Pradier C, Calvo G, Law MG, Kirk O, Phillips AN, and Lundgren JD. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 349: 1993-2003, 2003.
16. Fruebis J, Tsao TS, Javorschi S, Ebbets-Reed D, Erickson MR, Yen FT, Bihain BE, and Lodish HF. Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc Natl Acad Sci USA 98: 2005-2010, 2001.
17. Goudriaan JR, den Boer MAM, Rensen PCN, Febbraio M, Kuipers F, Romijn JA, Havekes LM, and Voshol PJ. CD36 deficiency in mice impairs lipoprotein lipase-mediated triglyceride clearance. J Lipid Res 46: 2175-2181, 2005.
18. Grundy SM, Wilhelmsen L, Rose G, Campbell RW, and Assman G. Coronary heart disease in high-risk populations: lessons from Finland. Eur Heart J 11: 462-471, 1990.
19. Hales CN and Randle PH. Immunoassay of insulin with insuiln antibody precipitate. Biochem J 88: 137-146, 1963.
20. Halwachs-Baumann G, Katzensteiner S, Schnedl W, Purstner P, Pieber T, and Wilders-Truschnig M. Comparative evaluation of three assay systems for automated determination of hemoglobin A1c. Clin Chem 43: 511-517, 1997.
21. Hellerstein MK, Grunfeld C, Wu K, Christiansen M, Kaempfer S, Kletke C, and Shackleton CH. Increased de novo hepatic lipogenesis in human immunodeficiency virus infection. J Clin Endocrinol Metab 76: 559-565, 1993.
22. Hopkins GJ and Barter PJ. Role of triglyceride-rich lipoproteins and hepatic lipase in determining the particle size and composition of high density lipoproteins. J Lipid Res 27: 1265-1277, 1986.
23. Kim HJ, Higashimori T, Park SY, Choi H, Dong J, Kim YJ, Noh HL, Cho YR, Cline G, Kim YB, and Kim JK. Differential effects of interleukin-6 and -10 on skeletal muscle and liver insulin action in vivo. Diabetes 53: 1060-1067, 2004.
24. Lewis GF, Uffelman KD, Szeto LW, Weller B, and Steiner G. Interaction between free fatty acids and insulin in the acute control of very low density lipoprotein production in humans. J Clin Invest 95: 158-166, 1995.
25. Luzi L, Perseghin G, Tambussi G, Meneghini E, Scifo P, Pagliato E, Del Maschio A, Testolin G, and Lazzarin A. Intramyocellular lipid accumulation and reduced whole body lipid oxidation in HIV lipodystrophy. Am J Physiol Endocrinol Metab 284: E274-E280, 2003.
26. Mallon PW, Wand H, Law M, Miller J, Cooper DA, and Carr A. Buffalo hump seen in HIV-associated lipodystrophy is associated with hyperinsulinemia but not dyslipidemia. J Acquir Immune Defic Syndr 38: 156-162, 2005.
27. Martinez E, Domingo P, Galindo MJ, Milinkovic A, Arroyo JA, Baldovi F, Larrousse M, Leon A, de Lazzari E, and Gatell JM. Risk of metabolic abnormalities in patients infected with HIV receiving antiretroviral therapy that contains lopinavir-ritonavir. Clin Infect Dis 38: 1017-1023, 2004.
28. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, and Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28: 412-419, 1985.
29. Mittendorfer B, Horowitz JF, and Klein S. Gender differences in lipid and glucose kinetics during short-term fasting. Am J Physiol Endocrinol Metab 281: E1333-E1339, 2001.
30. Patterson BW, Mittendorfer B, Elias N, Satyanarayana R, and Klein S. Use of stable isotopically labeled tracers to measure very low density lipoprotein-triglyceride turnover. J Lipid Res 43: 223-233, 2002.
31. Patterson BW, Zhao G, Elias N, Hachey DL, and Klein S. Validation of a new procedure to determine plasma fatty acid concentration and isotopic enrichment. J Lipid Res 40: 2118-2124, 1999.
32. Perry IJ, Wannamethee SG, Shaper AG, and Alberti KG. Serum true insulin concentration and the risk of clinical non-insulin dependent diabetes during long-term follow-up. Int J Epidemiol 28: 735-741, 1999.
33. Pinkney JH, Coppack SW, and Mohamed-Ali V. Effect of isoprenaline on plasma leptin and lipolysis in humans. Clin Endocrinol (Oxf) 48: 407-411, 1998.
34. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 37: 1595-1607, 1988.
35. Reeds DN, Mittendorfer B, Patterson BW, Powderly WG, Yarasheski KE, and Klein S. Alterations in lipid kinetics in men with HIV-dyslipidemia. Am J Physiol Endocrinol Metab 285: E490-E497, 2003.
36. Rubins HB, Robins SJ, Collins D, Nelson DB, Elam MB, Schaefer EJ, Faas FH, and Anderson JW. Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs High-Density Lipoprotein Intervention Trial (VA-HIT). Arch Intern Med 162: 2597-2604, 2002.
37. Sekhar RV, Jahoor F, Pownall HJ, Rehman K, Gaubatz J, Iyer D, and Balasubramanyam A. Severely dysregulated disposal of postprandial triacylglycerols exacerbates hypertriacylglycerolemia in HIV lipodystrophy syndrome. Am J Clin Nutr 81: 1405-1410, 2005.
38. Sekhar RV, Jahoor F, White AC, Pownall HJ, Visnegarwala F, Rodriguez-Barradas MC, Sharma M, Reeds PJ, and Balasubramanyam A. Metabolic basis of HIV-lipodystrophy syndrome. Am J Physiol Endocrinol Metab 283: E332-E337, 2002.
39. Serghides L, Nathoo S, Walmsley S, and Kain KC. CD36 deficiency induced by antiretroviral therapy. AIDS 16: 353-358, 2002.
40. Shahinian AH and Reinhold JG. Application of the phenol-hypochlorite reaction to measurement of ammonia concentrations in Kjeldahl digests of serum and various tissues. Clin Chem 17: 1077-1080, 1971.
41. Steele R. Influences of glucose loading and of injected insulin on hepatic glucose output. annals NY academy of science 82, 420-430, 1959.
42. Swanson B, Keithley JK, Zeller JM, and Sha BE. Lack of association between dyslipidemia and insulin resistance in HIV-infected persons treated with highly active antiretroviral therapy. Nutrition 20: 1022-1025, 2004.
43. Tershakovec AM, Frank I, and Rader D. HIV-related lipodystrophy and related factors. Atherosclerosis 174: 1-10, 2004.
44. Van Hall G, Steensberg A, Sacchetti M, Fischer C, Keller C, Schjerling P, Hiscock N, Moller K, Saltin B, Febbraio MA, and Pedersen BK. Interleukin-6 stimulates lipolysis and fat oxidation in humans. J Clin Endocrinol Metab 88: 3005-3010, 2003.
45. Van der Valk M, Bisschop PH, Romijn JA, Ackermans MT, Lange JM, Endert E, Reiss P, and Sauerwein HP. Lipodystrophy in HIV-1-positive patients is associated with insulin resistance in multiple metabolic pathways. AIDS 15: 2093-2100, 2001.
46. Vigouroux C, Maachi M, Nguyen TH, Coussieu C, Gharakhanian S, Funahashi T, Matsuzawa Y, Shimomura I, Rozenbaum W, Capeau J, and Bastard JP. Serum adipocytokines are related to lipodystrophy and metabolic disorders in HIV-infected men under antiretroviral therapy. AIDS 17: 1503-1511, 2003.
47. Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE, and Tataranni PA. Hypoadiponectinemia in obesity and type diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 86: 1930-1935, 2001.
48. Woerle HJ, Mariuz PR, Meyer C, Reichman RC, Popa EM, Dostou JM, Welle SL, and Gerich JE. Mechanisms for the deterioration in glucose tolerance associated with HIV protease inhibitor regimens. Diabetes 52: 918-925, 2003.
49. Wolfe RR. Radioactive and Stable Isotope Tracers in Biomedicine: Principles and Practice of Kinetic Analysis. New York: Wiley-Liss, 1992.